Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)

Funding Opportunity RFA-AI-20-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding

Related Links:

Source: BMJ Comments - Category: General Medicine Source Type: forums
The novel coronavirus strain, severe acute respiratory syndrome coronavirus-2, the causative agent of COVID-19 emerged in Wuhan, China, in December 2019 and is skyrocketing throughout the globe and become a global public health emergency. Despite promising preventive measures being taken, there is no vaccine or drug therapy officially approved to prevent or treat the infection. Everybody is waiting the findings of ongoing clinical trials in various chemical and biological products. This review is specifically aimed to summarize the available evidence and ongoing clinical trials of remdesivir as a potential therapeutic opti...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Recently, the White House unveiled its ambitious plan to develop a coronavirus vaccine before year ’s end. While many immediately questioned the feasibility of this timeline, we worry that not enough attention has gone to a different but equally important concern: Once we have a vaccine that works, who around the world will actually get to use […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions COVID-19 coronavirus Infectious Disease Source Type: blogs
[UCT] Researchers from the South African Tuberculosis Vaccine Initiative (SATVI) at the University of Cape Town (UCT), the Center for Global Infectious Disease Research - Seattle in the United States, and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to serve multiple functions in the fight against TB.
Source: AllAfrica News: Tuberculosis - Category: Infectious Diseases Source Type: news
A researcher leading Thailand's push to manufacture a coronavirus vaccine says its aim is to make it cost-effective and accessible to Southeast Asia, and play a part in preventing a supply shortage globally.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The global novel coronavirus pandemic afflicting everyone is showing mixed signs of activity. In some countries it appears to be easing, while in others it appears to be experiencing a resurgence. It’s not at all clear when the pandemic will end, but it’s unlikely to do so before 2021. What has become increasingly clear is that the toll of the pandemic will impact more than the people who come down with COVID-19. The mental health impact of living with a pandemic is being mostly ignored — for now. But as the deaths continue to rise, we need to pay close attention to the cost of the pandemic’s reperc...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: General Grief and Loss Health-related Mental Health and Wellness Policy and Advocacy coronavirus COVID-19 Source Type: blogs
Let us help you appreciate exactly how much work must go into producing a new vaccine — and how much faster than usual it's going now.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Vaccine efforts have seen biotech’s valuation skyrocket, despite having no products on the market
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
(Natural News) The Moderna vaccine company that’s attempting to use the mRNA technology platform to rapidly create a coronavirus vaccine has been widely accused of a pump-and-dump stock scheme involving the pumping of company stocks with widely-touted press releases that claim positive outcomes for phase 1 vaccine trials. But buried in Moderna’s own press release...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
(Natural News) Vaccine sorcery is underway folks, and you if don’t learn how to read vaccine literature right now, you are in for a rude awakening. Most healthcare workers have no clue what they’re injecting into their patient’s muscle tissue, they just regurgitate what they hear from the top – the script that’s siphoned, censured,...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
More News: Clinical Trials | Contracts | Funding | Grants | Infectious Diseases | Partnerships | Research | Vaccines